Published in Clinical Oncology Week, March 2nd, 2009
"Its effect on prostate cancer has not been evaluated. Noscapine was administered orally (300 mg/kg per day) for 56 days to PC3 human prostate cancer-bearing immunodeficient mice (n=10). Immunodeficient control mice (n=10) received only diluent in an identical regimen. Mean total tumour weight was 0.42 +/- 0.23 g and 0.97 +/- 0.31 g (p <0.001) in the noscapine-treated group and the control group, respectively, without evidence of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.